Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 May 29;19(1):104.
doi: 10.1186/s12883-019-1330-6.

Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS

Anne Marie Wills  1   2 , Jamie Garry  3 , Jane Hubbard  3 , Taylor Mezoian  4 , Christopher T Breen  4 , Courtney Ortiz-Miller  4 , Paige Nalipinski  5 , Stacey Sullivan  5 , James D Berry  4   6 , Merit Cudkowicz  4   6 , Sabrina Paganoni  4   6   7 , James Chan  8 , Eric A Macklin  6   8
Affiliations
Randomized Controlled Trial

Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS

Anne Marie Wills et al. BMC Neurol. .

Abstract

Background: Nutritional status is an important prognostic factor in Amyotrophic Lateral Sclerosis (ALS). We wished to study the safety, tolerability and efficacy of nutritional counseling with or without an mHealth application to maintain or increase body weight in ALS, compared to standard care.

Methods: In this randomized open-label, standard-of-care-controlled, single-center clinical trial, we randomly assigned adults with ALS to one of three nutritional interventions: counseling by their physician or nurse ("standard care"), counseling by a registered dietitian (RD) ("in-person"), or counseling supported by a mHealth app ("mHealth"). Both intervention arms received tailored nutrition recommendations and recorded dietary intake and weight biweekly (mHealth) or monthly (in-person). The primary outcome of weight and secondary and tertiary outcomes of calorie intake, ALSFRS-R, and quality of life (QOL) were recorded at each clinic visit and analyzed in an ITT mixed model analysis.

Results: A total of 88 participants were enrolled of whom 78 were included in this analysis. The three arms were well-balanced except for excess males in the mHealth arm and greater weight lost at baseline in the in-person arm. Participants in the mHealth arm increased their calorie intake at month 3 to an average of 94% (95% CI: 85, 103) of recommended calories, compared to 81% (95% CI: 72, 91, p = 0.06 vs. mHealth) in the standard care arm. After 6 months, calorie intake was not different among the three arms. Overall weight was stable across all three groups. QOL scores in the mHealth arm were stable over 3 months (0.3 points, 95% CI: - 1.7, 2.2) compared to worsening in standard care (- 2.1 points, 95% CI: - 4.0, - 0.2, p = 0.09 vs. mHealth), but all scores declined by 6 months. ALSFRS-R total scores declined by an average of - 2.6 points (95% CI: - 5.1, - 0.1) over 6 months in the mHealth arm (p = 0.13 vs. standard care) compared to - 5.8 points (95% CI: - 8.2, - 3.4, p = 0.74 vs. standard care) in the in-person and - 5.2 points (95% CI: - 7.6, - 2.9) in the standard care arm.

Conclusions: Nutritional counseling by a registered dietitian (with or without support by an mHealth app) is safe but did not maintain weight significantly better than standard care in ALS patients.

Trial registration: https://clinicaltrials.gov/ identifier NCT02418546. Registered April 16, 2015.

Keywords: ALS; Amyotrophic lateral sclerosis; Mobile health technology; Neurodegenerative disease; Nutrition; Nutritional counseling; Randomized controlled trial; mHealth.

PubMed Disclaimer

Conflict of interest statement

Anne-Marie Wills M.D., M.P.H. has received research funding from the ALS Association, has participated in clinical trials funded by Acorda, Biogen, Bristol-Myers Squibb, Sanofi/Genzyme, Pfizer and received consultant payments from Acorda, Mitsubishi Tanabe Pharma America, and Accordant, a CVS/Caremark disease management company.

Jamie Garry MS RD, reports grants from ALS Association, grants from NIH/NCRR, during the conduct of the study.

Jane Hubbard MS RD reports grants from ALS Association, grants from NIH/NCRR, during the conduct of the study.

Taylor Mezoian BS has nothing to disclose.

Christopher T. Breen BA has nothing to disclose.

Courtney Ortiz- Miller BA has nothing to disclose.

Paige Nalipinski MA SLP has nothing to disclose.

Stacey Sullivan MS SLP has nothing to disclose.

James Berry MD MPH, has been a consultant for MT Pharma, Denali Therapeutics, Anelixis Therapeutics, held a research fellowship position with Voyager Therapeutics, and been a Site Investigator for projects sponsored by Brainstorm Cell Therapeutics, Neuraltus, Cytokinetics, and Amylyx.

Merit Cudkowicz MD MSc. Has received grants from the NINDS, and received consulting funds from Lilly, MT Pharma, Orion, Cytokinetics, Biohaven, Waves and ImmunityPharm.

Sabrina Paganoni MD PhD, has received research funding from the ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, and Amylyx.

James Chan MA has nothing to disclose.

Eric A. Macklin PhD serves on Data and Safety Monitoring Boards for Acorda Therapeutics and Shire Human Genetic Therapies, received research funds and served on a Steering Committee for Acorda Therapeutics, and consulted for Myolex Inc. and Lavin Consulting.

Competing interests.

Figures

Fig. 1
Fig. 1
Consort flow diagram. Consort flow diagram showing the final disposition of participants in the study. Participants who did not return to the clinic for their month 6 visit but who supplied weight data for the primary analysis are marked with an asterisk
Fig. 2
Fig. 2
Change in weight and calories consumed by intervention group. a Change in weight from baseline by intervention group using measured clinic weights. b Calories consumed as a percent of calculated dietary requirements by intervention group at each visit. Red = mHealth; Blue = In-person dietary counseling; Green = Standard Care. Error bars represent 1 standard error around the mean
Fig. 3
Fig. 3
Change in ALSFRS-R and QOL by intervention group. a Change in ALSFRS-R from baseline by intervention group. b PROMIS SF v 1.1 Global Health QOL scores by intervention group and visit (higher scores are better). Red = mHealth; Blue = In-person dietary counseling; Green = Standard Care. Error bars represent 1 standard error around the mean
See this image and copyright information in PMC

References

    1. Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, Preux PM, Couratier P. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:628–634. doi: 10.1136/jnnp.2010.211474. - DOI - PubMed
    1. Mariosa D, Beard JD, Umbach DM, Bellocco R, Keller J, Peters TL, Allen KD, Ye W, Sandler DP, Schmidt S, et al. Body mass index and amyotrophic lateral sclerosis: a study of US military veterans. Am J Epidemiol. 2017;185:362–371. doi: 10.1093/aje/kww140. - DOI - PMC - PubMed
    1. Roubeau V, Blasco H, Maillot F, Corcia P, Praline J. Nutritional assessment of amyotrophic lateral sclerosis in routine practice: value of weighing and bioelectrical impedance analysis. Muscle Nerve. 2015;51:479–484. doi: 10.1002/mus.24419. - DOI - PubMed
    1. Kasarskis EJ, Neville HE. Management of ALS: nutritional care. Neurology. 1996;47:S118–S120. doi: 10.1212/WNL.47.4_Suppl_2.118S. - DOI - PubMed
    1. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75–82. doi: 10.1016/S1474-4422(10)70224-6. - DOI - PubMed

Publication types

Associated data